Skye Bioscience, Inc. (SKYE)

Skye Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	92.42	10.34	1.25	8.99	2.47	1.83
Cash & Cash Equivalents	92.42	10.34	1.25	8.99	2.47	1.83
Cash Growth	3357.29%	727.52%	-86.10%	263.28%	34.86%	-1.26%
Other Current Assets	2.15	1.31	7.69	0.62	0.19	0.16
Total Current Assets	94.57	11.65	8.94	9.61	2.66	1.99
Property, Plant & Equipment	0.26	0.28	0.16	0.23	0.01	0
Other Long-Term Assets	0.01	0.01	0.01	0.01	0	0
Total Long-Term Assets	0.27	0.29	0.17	0.24	0.01	0
Total Assets	94.84	11.94	9.11	9.86	2.67	2
Accounts Payable	1.1	1.16	1.79	0.9	0.38	0.14
Current Debt	4.68	4.44	1.93	2.06	0.06	0
Other Current Liabilities	10.02	8.3	8.4	0.95	0.34	0.83
Total Current Liabilities	15.8	13.9	12.12	3.91	0.79	0.97
Long-Term Debt	0.15	0.17	0	0.08	1.43	0.39
Other Long-Term Liabilities	0	0	0	0	0	0.09
Total Long-Term Liabilities	0.15	0.17	0	0.08	1.43	0.48
Total Liabilities	15.95	14.07	12.12	3.99	2.22	1.45
Total Debt	4.84	4.62	1.93	2.14	1.5	0.39
Debt Growth	1915.76%	139.50%	-9.78%	42.61%	286.96%	-71.56%
Retained Earnings	-109.4	-104.38	-66.74	-47.26	-38.73	-32.17
Shareholders' Equity	78.88	-2.13	-3.01	5.86	0.45	0.55
Net Cash / Debt	87.59	5.72	-0.68	6.85	0.98	1.45
Net Cash / Debt Growth	3499.40%	-	-	601.88%	-32.56%	191.28%
Net Cash Per Share	3.13	0.82	-0.31	4.21	1.05	2.13
Working Capital	78.77	-2.25	-3.18	5.7	1.88	1.02
Book Value Per Share	2.82	-0.30	-1.35	3.61	0.49	1.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).